Adaptive Biotechnologies (ADPT) Competitors $13.00 +0.37 (+2.93%) Closing price 04:00 PM EasternExtended Trading$13.28 +0.28 (+2.12%) As of 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ADPT vs. TWST, TXG, VCYT, GRFS, LEGN, RVMD, RYTM, RNA, NUVL, and ABVXShould you be buying Adaptive Biotechnologies stock or one of its competitors? The main competitors of Adaptive Biotechnologies include Twist Bioscience (TWST), 10x Genomics (TXG), Veracyte (VCYT), Grifols (GRFS), Legend Biotech (LEGN), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), Nuvalent (NUVL), and Abivax (ABVX). These companies are all part of the "medical" sector. Adaptive Biotechnologies vs. Its Competitors Twist Bioscience 10x Genomics Veracyte Grifols Legend Biotech Revolution Medicines Rhythm Pharmaceuticals Avidity Biosciences Nuvalent Abivax Adaptive Biotechnologies (NASDAQ:ADPT) and Twist Bioscience (NASDAQ:TWST) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk. Which has more risk & volatility, ADPT or TWST? Adaptive Biotechnologies has a beta of 1.92, suggesting that its share price is 92% more volatile than the S&P 500. Comparatively, Twist Bioscience has a beta of 2.36, suggesting that its share price is 136% more volatile than the S&P 500. Which has better earnings & valuation, ADPT or TWST? Adaptive Biotechnologies has higher earnings, but lower revenue than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Adaptive Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptive Biotechnologies$205.22M9.65-$159.49M-$0.82-15.85Twist Bioscience$362.27M4.76-$208.73M-$1.45-19.72 Do institutionals and insiders have more ownership in ADPT or TWST? 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 6.4% of Adaptive Biotechnologies shares are owned by company insiders. Comparatively, 3.0% of Twist Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media refer more to ADPT or TWST? In the previous week, Adaptive Biotechnologies had 3 more articles in the media than Twist Bioscience. MarketBeat recorded 12 mentions for Adaptive Biotechnologies and 9 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 1.11 beat Adaptive Biotechnologies' score of 0.48 indicating that Twist Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Twist Bioscience 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer ADPT or TWST? Adaptive Biotechnologies presently has a consensus target price of $12.38, suggesting a potential downside of 4.81%. Twist Bioscience has a consensus target price of $49.40, suggesting a potential upside of 72.79%. Given Twist Bioscience's higher probable upside, analysts plainly believe Twist Bioscience is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88Twist Bioscience 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.73 Is ADPT or TWST more profitable? Twist Bioscience has a net margin of -23.51% compared to Adaptive Biotechnologies' net margin of -59.07%. Twist Bioscience's return on equity of -29.03% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Adaptive Biotechnologies-59.07% -60.93% -23.03% Twist Bioscience -23.51%-29.03%-21.77% SummaryAdaptive Biotechnologies and Twist Bioscience tied by winning 8 of the 16 factors compared between the two stocks. Get Adaptive Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADPT vs. The Competition Export to ExcelMetricAdaptive BiotechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.98B$3.09B$5.82B$9.74BDividend YieldN/A2.23%3.84%4.09%P/E Ratio-15.8521.1431.1525.97Price / Sales9.65399.83475.57123.18Price / CashN/A43.0937.1558.38Price / Book11.028.079.116.39Net Income-$159.49M-$54.72M$3.26B$265.66M7 Day Performance-0.31%2.62%2.11%1.98%1 Month Performance23.46%7.63%5.12%1.33%1 Year Performance195.45%13.11%31.25%21.15% Adaptive Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADPTAdaptive Biotechnologies2.4889 of 5 stars$13.00+2.9%$12.38-4.8%+174.0%$1.98B$205.22M-15.85790Analyst RevisionTWSTTwist Bioscience4.1868 of 5 stars$27.63+7.8%$49.40+78.8%-40.0%$1.55B$312.97M-19.06990Positive NewsTXG10x Genomics3.9007 of 5 stars$12.31+0.2%$13.63+10.7%-43.1%$1.51B$610.78M-17.591,240VCYTVeracyte2.8594 of 5 stars$27.99+2.3%$40.90+46.1%-7.0%$2.15B$445.76M84.82790News CoveragePositive NewsGRFSGrifols3.721 of 5 stars$10.60-0.6%$10.30-2.8%+31.4%$7.33B$7.81B9.0623,822Short Interest ↑LEGNLegend Biotech3.7026 of 5 stars$36.24-2.1%$73.33+102.4%-37.1%$6.80B$627.24M-61.422,609RVMDRevolution Medicines4.4199 of 5 stars$34.70-0.9%$68.82+98.3%-19.4%$6.54B$11.58M-7.71250Positive NewsAnalyst RevisionRYTMRhythm Pharmaceuticals3.8106 of 5 stars$94.31+2.5%$101.57+7.7%+124.1%$6.11B$130.13M-31.33140News CoveragePositive NewsRNAAvidity Biosciences3.2165 of 5 stars$45.75-1.2%$67.00+46.4%-0.8%$5.96B$10.90M-15.25190Positive NewsOptions VolumeNUVLNuvalent3.284 of 5 stars$74.95+1.1%$119.60+59.6%-10.9%$5.32BN/A-15.3040News CoverageAnalyst ForecastInsider TradeABVXAbivax2.8837 of 5 stars$69.00-1.6%$92.33+33.8%+544.4%$5.30BN/A0.0061Short Interest ↑ Related Companies and Tools Related Companies Twist Bioscience Competitors 10x Genomics Competitors Veracyte Competitors Grifols Competitors Legend Biotech Competitors Revolution Medicines Competitors Rhythm Pharmaceuticals Competitors Avidity Biosciences Competitors Nuvalent Competitors Abivax Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADPT) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptive Biotechnologies Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptive Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access